The DESTINY-Breast 01-04 trials that studied TDXd in HER2+ and HER2-low breast cancers employed inclusion and exclusion criteria that excluded patients with active central nervous system metastases [2,4,5,7]. Here, ERBB2 is linked to breast cancer.